Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
Status:
Completed
Trial end date:
2006-05-19
Target enrollment:
Participant gender:
Summary
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of
SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in
subjects with previously untreated metastatic melanoma.